Wei Dai

Wei Dai

Auto-generated profile, based on publicly available information

Wei Dai

Beijing Institute of Pharmacology and Toxicology Beijing China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2016 in Molecules
Verified
Journal Article
Open access
PDF file
DXDian Xiao
Dian Xiao
FMFan-Hua Meng
Fan-Hua Meng
WDWei Dai
Wei Dai
ZYZheng Yong
Zheng Yong
JLJin-Qiu Liu
Jin-Qiu Liu
SLSong Li
Song Li
Ampakine compounds have been shown to reverse opiate-induced respiratory depression by activation of amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. However, their pharmacological exploitations are hindered by low blood-brain barrier (BBB) permeability and limited brain distribution. Here, we explored whether thiamine disulfide prodrugs with the ability of “lock-in” can be used to solve these problems. A series of thiamine disulfide prodrugs 7a–7f of ampakine compound LCX001 was synthesized and evaluated. The trials in vitro showed that prodrugs 7e, 7d, 7f possessed a certain stability in plasma and quickly decomposed in brain homogenate by the disulfide reductase. In vivo, prodrug 7e decreased the peripheral distribution of LCX001 and significantly increased brain distribution of LCX001 after i.v. administration. This compound showed 2.23- and 3.29-fold greater increases in the AUC0-t and MRT0-t of LCX001 in brain, respectively, than did LCX001 itself. A preliminary pharmacodynamic study indicated that the required molar dose of prodrug 7e was only one eighth that of LCX001 required to achieve the same effect in mice. These findings provide an important reference to evaluate the clinical outlook of ampakine compounds.

26 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JLJin-Feng Li
Jin-Feng Li
HCHai-Xia Chang
Hai-Xia Chang
JZJia-Ning Zhao
Jia-Ning Zhao
JBJin-Hao Bao
Jin-Hao Bao
WDWei Dai
Wei Dai
YLYun-Feng Li
Yun-Feng Li
Introduction: There is increasing evidence that astrocytes are involved in the therapeutic action of antidepressants. The fast antidepressant YL-0919 may interact with activation of astrocytic sigma-1 receptors (sigma-1R).Methods: In this study, function of astrocytic sigma-1R in ventral hippocampus (vHIP) mediating the rapid antidepressant effect of YL-0919 were investigated. Adeno-associated virus (AAV) expressing shRNA was constructed to knock down astrocytic sigma-1R in vHIP, and the role of astrocytic sigma-1R on the rapid antidepressant action of YL-0919 were tested in chronic restraint stress (CRS) model of mice. Small interfering RNA (siRNA) was used to knock down sigma-1R in primary astrocytes, and we explored the mitochondrial function and BDNF expression of primary astrocytes after YL-0919 and siRNA treatments. Result: The results indicated knocking down astrocytic sigma-1R in vHIP induced anxiety-like and depressive-like behavior in mice, and blocked the rapid anti-depressant and anxiolytic effects of YL-0919. Knocking down sigma-1R in primary astrocytes inhibited the YL-0919 induced enhancement of mitochondrial function and increased level of BDNF expression. In addition, increased BDNF in vHIP might play a role in fast antidepressant impact of YL-0919. Taken together, the data provide further evidence for a role of astrocyte receptors in the mechanisms of action of antidepressants.Conclusion: Taken together, these results reveal increased BDNF in vHIP by affecting glial cells might be one of the significant mechanisms of fast antidepressant effect of YL-0919. The data provide further evidence for a role of astrocyte receptors in the mechanisms of action of antidepressants.

6 March 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
LCLin-Yu Cui
Lin-Yu Cui
JDJing-Yao Duan
Jing-Yao Duan
JYJiao-Zhao Yan
Jiao-Zhao Yan
JWJing-Ya Wang
Jing-Ya Wang
PRPeng Ren
Peng Ren
YLYun-Feng Li
Yun-Feng Li